TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Multicenter, Single Arm Feasibility Study of the Safety and Performance of GRADION™ Hip Total Cartilage Replacement (TCR)™ in the Treatment of Degenerative Joint Disease of the Hip

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary hip surgery for Noninflammatory Degenerative Joint Disease (NIDJD) such as osteo/degenerative arthritis, and is indicated for cartilage replacement~* Skeletally mature or at least 18 years of age and has normal anatomy~* Patient signs the Informed Consent form~* Failed medical management~* There will be size limitations on patients also - available size range is 46mm-54mm.~Exclusion Criteria:~* Allergic to polyether urethane, sodium polyacrylate, bone cement or any of its components~* Previous fusion, acute femoral neck fracture and/or above knee amputation~* Revision of any previous hip procedure~* Slipped capital femoral epiphysis (SCFE)~* Rheumatoid arthritis~* AVN

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GRADION™ Hip Total Cartilage Replacement (TCR)™ (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pre-recovery Bedside Liver Biopsy in Brain Death Organ Donors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neurological death donors in whom brain death determination is imminent~* First person or next of kin consent for research becomes available~* High risk donor, as defined by the following criteria i) Known liver disease ii) Hepatitis BsAg, BcAb, B DNA, Hepatitis C Ab or Hepatitis C RNA positivity iii) Age \>= 50 iv) Any of the following risk factors for fatty liver disease a) BMI \>= 30 b) History of Type 2 Diabetes Mellitus c) Ultrasound, Computerized Tomography or other imaging modalities suggesting steatosis v) Any of the following risk factors for chronic liver disease~  1. Greater than 2 drinks of alcohol daily currently or in their history~ 2. Current IV drug use~ 3. Ultrasound, Computerized Tomography or other imaging modalities suggesting cirrhosis~Exclusion Criteria:~* Donation after cardiac death donors~* Live organ donors~* No first person consent and next of kin decline research consent~* Donors in whom it has been established the liver will not be shared~* Donors in whom percutaneous liver biopsy has been performed within the past month for any indication and the biopsy results are available and considered reliable.~* Donor with a contraindication to liver biopsy, including INR \> 2, PTT \> 75, Platelets \< 70,000, history of coagulopathy, current or recent use (within 7 days) of antiplatelet agent such as aspirin or Plavix, and hemodynamic instability defined as a MAP less than 65mmHg.~* Inability to position donor appropriately for performance of PPB~* Unavailability of pathology staff to analyze specimen in a timely manner

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): In this group a liver biopsy will not be performed. All management would be as per standard of practice
- Percutaneous liver biopsy (Type: ACTIVE_COMPARATOR): In this group a percutaneous biopsy of the liver will be performed prior to organ recovery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:1. Pregnant women with arrested preterm labor between 24+0 to 33+6 weeks pregnant.~2. Intact membranes 3. Singleton pregnancy 4. Greater than or equal to 18 years of age 5. Cervical dilation less than or equal to 4cm Exclusion Criteria:1. Any contraindication to on-going pregnancy 2. Placental abruption 3. Placenta previa 4. Lethal fetal anomalies 5. Premature rupture of membranes 6. Multiple gestation 7. Less than 18 years old 8. Known allergy to any component of the study medication or placebo 9. Severe maternal medical illness

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Progesterone (Type: ACTIVE_COMPARATOR): Progesterone 400mg per vagina qhs.
- Polyethylene glycol&hydrogenated vegetable oil (Type: PLACEBO_COMPARATOR): Polyethylene glycol\&hydrogenated vegetable oil per vagina

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ADVANTAGE® Prosthetic Heart Valve Long-term Follow-up Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participated in the ADVANTAGE Prosthetic Heart Valve Study in Herz- und Diabeteszentrum (Bad Oeynhausen) or Deutsches Herzzentrum (Munich)~* Signed and dated patient data release form~* Available for follow-up~Exclusion Criteria:~* High probability of non-adherence to physician's follow-up requirements

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Advantage prosthetic heart valve (Type: None): All patients who were enrolled and implanted with an Advantage valve in the Herzzentrum Nordrhein-Westfalen (Bad Oeynhausen, Germany) and Deutsches Herzzentrum München (Munich, Germany) during the previous Advantage clinical study study and who agree to participate in this long-term follow-up study by informed consent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pre-operative Treatment With Erythropoietin and Iron Supplement in Cardiac Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Undergoing isolated Coronary Artery Bypass Grafting operation or Aortic Valve Repair (AVR).~2. Preoperative Hb \< 7 mmol/l.~Exclusion Criteria:~1. Off pump surgery.~2. Combination surgery.~3. Re-operation.~4. Emergency operation.~5. Patients with bleeding disturbances; e.g, hemophilia and patients with chronic liver disease.~6. Concomitant use of cyclosporine prior to, during or following surgery.~7. Female patients who are pregnant or planning to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erythropoietin Iron (Type: OTHER): Erythropoietin and iron:~Administration of Erythropoietin (600 IU/kg (14.4 g/L)) twice weekly for three weeks .~Administration of Iron (Ferinject (iron(III)carboxymaltose)) intravenously 1000 mg once.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Treatment of Lisfranc Injuries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Stratum 1:~* Nondislocated fractures affecting tarsometatarsal (TMT) joints II and III~* Dislocation \<5mm between medial cuneiforme and base of II metatarsal (MT)~* No fractures affecting TMT joints IV and V~Stratum 2:~* Affected joints TMT II- III + any other TMT~* Any dislocation \>2mm (fracture or TMT joint)~* Dislocation \>5mm between medial cuneiforme and base of II MT~Exclusion Criteria:~* Open fractures~* Extra-articular metatarsal (MT) fractures~* Extremely comminuted fractures with bone loss, and slight chance of gaining proper reduction with screws~* Patients with multiple fractures~* Patients with weak co-operation (dementia, alcohol use, etc.)~* Patients with significant neuropathy or some other neurological condition, diabetes and rheumatoid arthritis~* Patients with severe circulatory disorder of the lower limb~* Injuries over 14 days~* Patients with previous foot injury or surgery~* Pregnancy~* Patients who refuse to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Open reduction and internal fixation (Type: ACTIVE_COMPARATOR): After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
- Primary Arthrodesis (Type: ACTIVE_COMPARATOR): After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
- Conservative treatment (Type: ACTIVE_COMPARATOR): Non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Unilateral idiopathic sudden sensorineural hearing loss (ISSNHL) with onset within 72 hours prior to study treatment;~2. Mean hearing threshold of equal to or worse than (≥) 60 dB averaged across those 3 contiguous air conduction audiometric pure tone frequencies that show the highest mean hearing loss compared with the unaffected contralateral ear or, in case of history of asymmetric hearing, corresponding values from a pre-existing audiogram for the affected ear not older than 2 years prior to the ISSNHL incident (defined as pure tone average, PTA);~3. Mean hearing loss of equal to or worse than (≥) 40 dB averaged across the air conduction thresholds at the pure tone average frequencies compared with the unaffected contralateral ear or, in case of history of asymmetric hearing, corresponding values from a preexisting audiogram for the affected ear not older than 2 years prior to the ISSNHL incident;~4. Age ≥ 18 years on the day of screening;~Exclusion Criteria:~1. Bilateral ISSNHL;~2. Acute hearing loss from noise trauma, barotrauma or head trauma;~3. Air-bone gap greater than 20 dB at the average of 3 contiguous test frequencies below 4 kHz, when the air-bone gap is measurable;~4. History of autoimmune hearing loss, radiation-induced hearing loss, endolymphatic hydrops or Menière's disease in either ear;~5. History of chronic inflammatory or suppurative ear disease or cholesteatoma in the affected ear;~6. Current evidence or history of acoustic neuroma or other retrocochlear damage in the affected ear;~7. History of otosclerosis in the affected ear;~8. Suspected perilymph fistula or membrane rupture in the affected ear;~9. Congenital hearing loss;~10. History of ISSNHL in the past 2 years;~11. Otitis media or otitis externa that is ongoing or ended within 7 days prior to study treatment;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo gel for intratympanic use
- AM-111 0.4 mg/ml (Type: EXPERIMENTAL): AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
- AM-111 0.8 mg/ml (Type: EXPERIMENTAL): AM-111 gel for intratympanic use (0.8 mg/ml AM-111)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Aged 4 weeks or younger (0-28 days)~* \>36 weeks gestational age at birth~* Birth weight ≥2500 g~* Plasma ammonia level at presentation \>150 mcmol/L~* PA or MMA presumed or established diagnosis as follows (one of the following):~  1. Acidosis at presentation, pH \<7.3 OR~ 2. Plasma acylcarnitine analysis either alone or as part of newborn screening, demonstrating C3 \>4 mcmol/L OR~ 3. Diagnosed, or sibling diagnosed with PA by semi-quantitative urine organic acid analysis, defined as presence of elevated methylcitric acid and no evidence of biotin related disorders in the organic acid analysis OR~ 4. Diagnosed, or sibling diagnosed with MMA by semi-quantitative urine organic acid analysis, defined as elevation of methylmalonic acid and no evidence of vitamin B12 dependent disorder on plasma amino acid analysis~* Able to receive medications orally, by nasogastric (NG)-tube or by gastric (G)-tube~* No concomitant illness which would preclude safe participation as judged by the investigator~* Signed informed consent by the subject's legally acceptable representative~* After initial enrollment, criteria 3 or 4 (definitive diagnosis of the patient) must be fulfilled prior to discharge from initial admission in order to remain in the study.~Exclusion Criteria~* Had any prior hyperammonemic episode~* Administration of NCG within 7 days of participation in the study~* Use of any other investigational drug, biologic, or therapy, with the exception of sodium benzoate or sodium phenylacetate if the latter were administered prior to diagnosis by acylcarnitine analysis (diagnostic inclusion criterion 2), or organic acid analysis (diagnostic inclusion criteria 3 \& 4)~* Planned participation in any other clinical trial~* Diagnosis of any medical condition causing hyperammonemia which is not PA or MMA.~* Any clinical or laboratory abnormality or medical condition that, at the discretion of the investigator, may put the subject at an additional risk by participating in this study~* Had a liver transplant or is scheduled for a liver transplant~* Is not expected to be compliant with this study in terms of returning to site for subsequent episodes of hyperammonemia crises or for long-term follow-up

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 4 Weeks
- Healthy Volunteers: f

Study Arms:
- N-Carbamylglutamate (Type: EXPERIMENTAL): Active NCG \& Standard of Care
- Placebo (Type: PLACEBO_COMPARATOR): Standard of Care therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Conventional Versus Mini-Sternotomy for Aortic Valve Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Indication of isolated aortic valvular replacement~* Preoperative ASA class \< = 3~* Left ventricular ejection fraction \> = 40%~* Signed informed consent~Exclusion Criteria:~* Aortic or mitral insufficiency \> 3~* History of cardiac surgery~* Acute pulmonary edema~* Endocarditis~* Chronic renal insufficiency decompensation~* Operative coagulation disorders regardless of etiology

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Systems Biology of Gastrointestinal and Related Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* Any patient 18 years old or older that schedules a visit to WAGI clinics or endoscopy center~* Able to use electronic communications~* Able to communicate in English~* Consent to participate in the study~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ulcerative Colitis (Type: None): Participants with ulcerative colitis.
- Crohn's Disease (Type: None): Participants with Crohn's disease.
- Obesity (Type: None): Participants that are obese.
- Colon Polyps (Type: None): Participants with colon polyps.
- Eosinophilic esophagitis (Type: None): Participants with Eosinophilic esophagitis
- Gastroesophageal Reflux Disease (GERD) (Type: None): Participants with Gastroesophageal Reflux Disease (GERD).
- Gastritis (Type: None): Participants with gastritis.
- Gastric ulcers (Type: None): Participants with gastric ulcers.
- Duodenal ulcers (Type: None): Participants with duodenal ulcers.
- Intestinal metaplasia (Type: None): Participants with intestinal metaplasia (risk factor for esophageal cancer).
- Gastric Cancer (Type: None): Participants with gastric cancer.
- Lymphocytic/Microscopic Colitis (Type: None): Participants with Lymphocytic/Microscopic Colitis.
- Celiac Sprue (Type: None): Participants with Celiac Sprue.
- Irritable Bowel Syndrome (IBS) (Type: None): Participants with IBS.
- Small intestinal bacterial overgrowth (SIBO) (Type: None): Participants with SIBO.
- Non-alcoholic Fatty Liver Disease (NAFLD) (Type: None): Participants with NAFLD.
- Gallstone disease (Type: None): Participants with Gallstone disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Different Exercises Interventions in Post-menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* being postmenopausal (amenorrhea of at least 12 months and \[FSH\]\> 40 mlU/ml); be controlled hypertension; not to undergo drug treatment with β-blockers; not make use of sex hormone therapies; do not present physical problems or cardiovascular complications that prevent the performance of physical exercises; present attestation of a cardiologist proving that they are able to perform physical exercises.~Exclusion Criteria:~* Do not attend the collection site on the day and time programmed more than once in the acute phase of the study; missing more than 2 consecutive sessions or 6 alternates in the chronic phase of the study; unable to perform the proposed training protocols; change in drug therapy during the intervention.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks without perform exercise training.
- Alternative training (Type: EXPERIMENTAL): Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks of high intensity interval training.
- Conventional training (Type: EXPERIMENTAL): Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks of moderate intensity continuous training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy female subjects~Exclusion Criteria:~* Evidence or history of clinically significant findings at screening

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Fesoterodine (Type: EXPERIMENTAL): Tablets
- Placebo (Type: PLACEBO_COMPARATOR): Tablets
- Solifenacin (Type: ACTIVE_COMPARATOR): Tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy